The FDA has now approved three CAR-T cell therapies for follicular lymphoma, with the most recent being Breyanzi (lisocabtagene maraleucel), which received accelerated approval on May 15, 2024. This latest addition to the treatment arsenal showed a remarkable overall response rate of 95.7% in clinical trials, offering new hope for adults with relapsed or refractory follicular lymphoma who have exhausted at least two prior lines of systemic therapy. For the estimated 15,000 Americans diagnosed with follicular lymphoma each year, these approvals represent a fundamental shift in how the disease is treated when conventional options fail.
This wave of approvals began in March 2021, when Yescarta became the first CAR-T therapy cleared for indolent follicular lymphoma, followed by Kymriah and now Breyanzi. All three are CD19-directed therapies, meaning they work by reprogramming a patient’s own immune cells to recognize and attack cancer cells bearing the CD19 protein. For readers of this site who follow developments in cellular therapies and neuroscience, the engineering behind CAR-T is worth understanding — it sits at the intersection of immunology, gene therapy, and personalized medicine, and some of the same principles are being explored in neurological conditions. This article covers what CAR-T therapy actually involves, how the three approved options compare in efficacy and safety, what the real-world limitations are, and what patients and caregivers should know before pursuing this treatment path.
Table of Contents
- What Is CAR-T Cell Therapy and Why Was It Approved for Follicular Lymphoma?
- How Do the Three Approved CAR-T Therapies Compare?
- Understanding the Risks — Cytokine Release Syndrome and Neurologic Toxicity
- Who Is Eligible and How to Access CAR-T Treatment
- What Caregivers and Families Need to Know About the Recovery Period
- Breyanzi’s Expanding Approvals Signal Broader CAR-T Applications
- The Future of CAR-T and Cellular Therapy in Lymphoma
- Conclusion
- Frequently Asked Questions
What Is CAR-T Cell Therapy and Why Was It Approved for Follicular Lymphoma?
CAR-T cell therapy is not a drug in the traditional sense. It is a living treatment made from a patient’s own blood. The process begins with leukapheresis, where T cells are collected from the patient’s bloodstream and sent to a manufacturing facility. There, the T cells are genetically engineered to express chimeric antigen receptors — the “CAR” in CAR-T — that recognize the CD19 protein found on the surface of B-cell lymphomas, including follicular lymphoma. These modified cells are then expanded in the lab and infused back into the patient, where they seek out and destroy cancer cells. Follicular lymphoma is the most common type of indolent, or slow-growing, non-Hodgkin lymphoma.
While it often responds well to initial treatment with anti-CD20 antibodies like rituximab and chemotherapy, many patients relapse repeatedly, and with each relapse the disease can become harder to control. Before CAR-T, patients who had failed multiple treatment lines faced diminishing returns with each subsequent therapy. The approval of these three CAR-T products addressed a genuine unmet need — a treatment that could produce deep, durable responses in a heavily pretreated population. The approval pathway for each product rested on single-arm clinical trials showing exceptionally high response rates. Yescarta’s ZUMA-5 trial demonstrated a 94% overall response rate with 79% achieving complete responses. Kymriah’s ELARA trial showed an 86% overall response rate and 69.1% complete response rate in patients who had received a median of four prior therapies. And Breyanzi’s TRANSCEND-FL trial reported a 95.7% overall response rate, with the median duration of response not yet reached after 16.8 months of follow-up — meaning most patients who responded were still in remission when the data was analyzed.
How Do the Three Approved CAR-T Therapies Compare?
While Yescarta, Kymriah, and Breyanzi all target CD19 and are indicated for the same patient population — adults with relapsed or refractory follicular lymphoma after two or more prior lines of therapy, including an anti-CD20 antibody and an alkylating agent — they are not interchangeable products. Each has a different manufacturing process, different T cell compositions, and different clinical trial data supporting its use. Yescarta, made by Gilead’s Kite Pharma, was the pioneer, earning its follicular lymphoma indication in March 2021. Kymriah, from Novartis, followed. Breyanzi, from Bristol Myers Squibb, arrived most recently with what may be the strongest efficacy signal of the three, though direct head-to-head comparisons have never been conducted. The numbers are worth examining carefully. Yescarta’s 94% overall response rate and 79% complete response rate came from the ZUMA-5 study.
Kymriah’s ELARA trial reported 86% and 69.1%, respectively, though its patient population had a higher median number of prior therapies, which makes direct comparison difficult. Breyanzi’s 95.7% overall response rate is numerically the highest, and its durability data — median duration of response not reached at 16.8 months — is encouraging. However, these were all single-arm trials with different patient populations, different enrollment criteria, and different follow-up periods. No oncologist would tell you that one product is definitively superior to another based on cross-trial comparisons alone. What does differ meaningfully across the three products is their safety profiles and practical considerations like manufacturing turnaround time, which can vary from two to four weeks. For a patient whose disease is progressing, even a week’s difference matters. The choice between them often comes down to institutional access, insurance coverage, physician experience with a particular product, and the specific patient’s clinical situation. If your treatment center is certified for one product but not another, that may make the decision for you.
Understanding the Risks — Cytokine Release Syndrome and Neurologic Toxicity
CAR-T therapy is not a gentle treatment. When those engineered T cells activate and begin killing cancer cells in large numbers, they trigger a massive inflammatory response known as cytokine release syndrome, or CRS. Symptoms can range from mild fever and fatigue to life-threatening drops in blood pressure, organ dysfunction, and the need for intensive care. Breyanzi’s prescribing information lists CRS as the most common adverse reaction, occurring in more than 20% of patients, along with headache, musculoskeletal pain, fatigue, constipation, and fever. More concerning is the risk of neurologic toxicity, sometimes called immune effector cell-associated neurotoxicity syndrome, or ICANS. Patients can experience confusion, difficulty speaking, tremors, seizures, and in rare cases, fatal cerebral edema.
This is particularly relevant for readers interested in brain health. The neurologic effects are usually temporary and reversible, but they can be severe and frightening. All three approved CAR-T therapies carry warnings about these risks, and Breyanzi specifically operates under a Risk Evaluation and Mitigation Strategy, or REMS, due to the potential for fatal or life-threatening CRS and neurologic toxicities. Because of these risks, CAR-T therapy can only be administered at certified treatment centers with teams trained to manage these complications. Patients typically remain near the treatment center for at least four weeks after infusion for monitoring. For older adults or those with pre-existing cognitive concerns, the potential for neurologic side effects demands a thorough conversation with the care team about baseline cognitive status and monitoring plans. This is not a treatment to pursue without fully understanding what the recovery period looks like.
Who Is Eligible and How to Access CAR-T Treatment
The current FDA-approved indication for all three CAR-T products in follicular lymphoma is narrow and specific: adults with relapsed or refractory disease who have already failed at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent. This means CAR-T is not a first-line treatment. A patient newly diagnosed with follicular lymphoma will not be offered CAR-T. It is reserved for those who have run through conventional options — typically rituximab-based chemotherapy, possibly lenalidomide combinations, possibly PI3K inhibitors — and whose disease continues to progress or returns. The practical barriers to access are significant. CAR-T therapies are among the most expensive treatments in medicine, with list prices often exceeding $400,000 for the product alone, not including hospitalization, monitoring, and management of side effects.
Insurance coverage varies, and the prior authorization process can be lengthy. Medicare covers CAR-T therapy, but not all commercial insurers do so readily. Geographic access is another hurdle — certified treatment centers are concentrated in major academic medical centers, often requiring patients to travel and stay away from home for weeks. For patients and caregivers weighing CAR-T against other options, the tradeoff is essentially this: CAR-T offers the highest response rates available for relapsed follicular lymphoma, with the potential for durable remissions, but it comes with serious short-term risks, high costs, logistical complexity, and a recovery period that can stretch for months. Newer targeted therapies like bispecific antibodies are emerging as alternatives that can be given in outpatient settings with different risk profiles. The decision is deeply personal and should involve a hematologist-oncologist who specializes in lymphoma.
What Caregivers and Families Need to Know About the Recovery Period
The weeks following CAR-T infusion are intensive, and for many patients, a dedicated caregiver is not optional — it is required. Most treatment centers mandate that patients have a caregiver available around the clock for at least the first 30 days after infusion. The caregiver’s role includes monitoring for signs of CRS and neurologic toxicity, driving the patient to frequent follow-up appointments (patients are restricted from driving for at least eight weeks), managing medications, and providing emotional support during what can be an isolating and physically draining period. For families already managing care responsibilities — perhaps for a loved one with dementia or another chronic condition — adding a CAR-T recovery period creates a compounding burden that needs to be planned for honestly.
The neurologic side effects, even when temporary, can be distressing to witness. Confusion, word-finding difficulty, and personality changes during the acute toxicity phase can mimic or be confused with neurological conditions, which adds complexity for caregivers who may already be attuned to cognitive changes in other family members. Patients should also be aware that immune suppression following CAR-T therapy is prolonged. Because the treatment destroys normal B cells along with cancerous ones, patients may need immunoglobulin replacement therapy for months or years and remain at elevated risk for infections. This has practical implications for household planning, especially in homes with vulnerable individuals.
Breyanzi’s Expanding Approvals Signal Broader CAR-T Applications
Breyanzi’s trajectory illustrates how CAR-T therapy continues to expand beyond its original indications. After its May 2024 accelerated approval for follicular lymphoma, Bristol Myers Squibb secured approval in the EU and UK in March 2025 for relapsed or refractory indolent follicular lymphoma. Then, on December 4, 2025, the FDA approved Breyanzi for relapsed or refractory marginal zone lymphoma, making it the first and only CAR-T therapy approved for that indication.
Each new approval broadens the population of patients who can benefit from this technology. This pattern of sequential approvals across related cancers reflects a deliberate clinical development strategy. Once a CAR-T product demonstrates efficacy in one CD19-positive lymphoma, there is strong scientific rationale to test it in others. For patients with rarer lymphoma subtypes who previously had limited options, these expansions are meaningful — they open doors that were closed just a few years ago.
The Future of CAR-T and Cellular Therapy in Lymphoma
The next frontier for CAR-T in follicular lymphoma involves moving the therapy earlier in the treatment sequence, potentially after just one prior line of therapy rather than two. Clinical trials are underway evaluating this approach, and if the data supports it, the eligible patient population could expand significantly. There is also active research into “off-the-shelf” allogeneic CAR-T products that would not require manufacturing from each individual patient’s cells, which could reduce wait times and costs dramatically.
Beyond lymphoma, the principles behind CAR-T are being adapted for other diseases, including autoimmune conditions and, in early preclinical work, neurological diseases. The idea of engineering immune cells to clear specific targets — whether malignant cells or misfolded proteins — has implications that reach well beyond oncology. For now, the three approved CAR-T therapies for follicular lymphoma represent one of the clearest success stories in modern cancer treatment, but they are almost certainly just the beginning of what this platform technology can do.
Conclusion
The approval of three CAR-T cell therapies for follicular lymphoma — Yescarta in 2021, Kymriah shortly after, and Breyanzi in 2024 — has transformed the treatment landscape for patients with relapsed or refractory disease. Response rates ranging from 86% to 95.7% in clinical trials represent outcomes that were unimaginable a decade ago for this patient population. Breyanzi’s continued expansion into marginal zone lymphoma and its approval in the EU and UK underscore the momentum behind this approach.
Yet CAR-T therapy remains a serious undertaking with real risks, significant costs, and demanding logistics. It is not the right choice for every patient, and it requires a care team experienced in managing its unique complications. For patients and families navigating these decisions — particularly those already managing complex care situations — the key is honest conversation with a lymphoma specialist about whether the potential benefits justify the burdens. The science is remarkable, but the human side of this treatment demands just as much attention.
Frequently Asked Questions
What is CAR-T cell therapy?
CAR-T cell therapy involves collecting a patient’s own T cells from their blood, genetically engineering those cells in a laboratory to recognize and attack cancer cells bearing the CD19 protein, and then infusing the modified cells back into the patient. It is a one-time, personalized treatment.
How many CAR-T therapies are approved for follicular lymphoma?
Three — Yescarta (axicabtagene ciloleucel) by Gilead/Kite Pharma, Kymriah (tisagenlecleucel) by Novartis, and Breyanzi (lisocabtagene maraleucel) by Bristol Myers Squibb. All are approved for adults with relapsed or refractory follicular lymphoma after two or more prior lines of systemic therapy.
What are the response rates for CAR-T therapy in follicular lymphoma?
In clinical trials, Yescarta showed a 94% overall response rate with 79% complete responses (ZUMA-5 trial), Kymriah showed 86% overall response and 69.1% complete response (ELARA trial), and Breyanzi showed 95.7% overall response with median duration of response not yet reached at 16.8 months of follow-up (TRANSCEND-FL trial).
What are the main risks of CAR-T therapy?
The most serious risks are cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ dysfunction, and neurologic toxicity, which can cause confusion, difficulty speaking, and in rare cases seizures. Breyanzi carries a Risk Evaluation and Mitigation Strategy (REMS) because of the potential severity of these side effects.
Can CAR-T therapy be used as a first treatment for follicular lymphoma?
No. All three approved CAR-T therapies are currently indicated only for patients who have already failed at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent. Clinical trials are exploring whether CAR-T could be used earlier in treatment.
How long does the CAR-T treatment process take?
From cell collection to infusion, manufacturing typically takes two to four weeks. After infusion, patients must remain near the treatment center for at least four weeks for monitoring, and driving restrictions last at least eight weeks. Full immune recovery can take months to over a year.
